PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2013 | 11 | 4 | 594-603
Article title

A novel 2-(2-methyl-2-nitrovinyl)-furan ectoparasitic drug: physicochemical characterization and determination of the raw material by gas chromatography mass spectrometry

Content
Title variants
Languages of publication
EN
Abstracts
EN
2-(2-methyl-2-nitrovinyl)-furan (NVF) has recently been synthesized and the pharmaceutical industry interest in this compound has grown due to its antibacterial, fungicidal and anti-ectoparasitic activities. Therefore, the physicochemical characterization of new drug was conducted. In addition, two rapid, simple and suitable GC methods were developed for determination of NVF. Analyses were carried out with an Agilent DB-5ms capillary column (60 m × 0.25 mm i.d., 0.25 µm film thickness). The GC-FID analysis employed splitless mode of injection, oven/injector/detector temperature of 160/230/280°C and nitrogen carrier at the flow of 5.0 mL min−1. The GC-MS analysis employed splitless mode of injection, helium carrier at the flow of 1.5 mL min−1, column temperature program with 2 min at 100°C, ramp at 50°C min−1 to 260°C and injector and detector temperature of 250 and 290°tC, respectively. The MS conditions were ionization voltage, 70 eV; mass range, m/z 40–350; and ion source temperature, 200°C. The analysis time took less than 6 min. The results obtained in the validation of the methods suggest that these methods are economic, precise, accurate and linear over the range of analysis. The methods were successfully employed during the synthesis of NVF in order to ensure the quality of the raw material. [...]
Publisher

Journal
Year
Volume
11
Issue
4
Pages
594-603
Physical description
Dates
published
1 - 4 - 2013
online
23 - 1 - 2013
Contributors
  • Center of Chemical Bioactive, Central University “Marta Abreu de Las Villas”, 54830, Santa Clara, Cuba
  • Center of Chemical Bioactive, Central University “Marta Abreu de Las Villas”, 54830, Santa Clara, Cuba
author
  • Center of Chemical Bioactive, Central University “Marta Abreu de Las Villas”, 54830, Santa Clara, Cuba
author
  • Center of Chemical Bioactive, Central University “Marta Abreu de Las Villas”, 54830, Santa Clara, Cuba
  • Department of Natural Sciences, Federal University of São João del Rei, 36301-160, São João del Rei, Minas Gerais, Brazil, keyllerbastosborges@gmail.com
References
  • [1] R. Draisci, L. Giannetti, L. Lucentini, L. Palleschi, G. Brambilla, L. Serpe, P. Gallo, J. Chromatogr. A 777, 201 (1997) http://dx.doi.org/10.1016/S0021-9673(97)00247-1[Crossref]
  • [2] D.R. Mccalla, Environ. Mutag. 5, 745 (1983) http://dx.doi.org/10.1002/em.2860050512[Crossref]
  • [3] Commission Regulation (EC) 1442/95 of 26 June 1995 amending Annexes I, II, III and IV of Regulation (ECC) No 2377/90 laying down a Community Procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin. Official Journal of the European Communities, L143, 26 (1995)
  • [4] L.H. Vroomen, P.J. van Bladeren, J.P. Groten, C.J. Wissink, H.A. Kuiper, M.C. Berghmans, Drug Metab. Rev. 22, 663 (1990) http://dx.doi.org/10.3109/03602539008991460[Crossref]
  • [5] J.E.M. Van Koten-Vermeulen, Report of the 40thMeeting of the Joint FAO/WHO Expert Committee On Food Additives (JECFA) (World Health Organisation, Geneva, 1993) 85
  • [6] S.P. Khong, E. Gremaud, J. Richoz, T. Delatour, P.A. Guy, R.H. Stadler, P. Mottier, J. Agric. Food Chem. 52, 5309 (2004) http://dx.doi.org/10.1021/jf0401118[Crossref]
  • [7] M.M. Vasheghani, M. Bayat, F. Rezaei, A. Bayat, M. Karimipour, Photomed. Laser Surg. 26, 1 (2008) http://dx.doi.org/10.1089/pho.2007.2103[Crossref]
  • [8] A. Roychowdhury, A. Pan, D. Dutta, A.K. Mukhopadhyay, T. Ramamurthy, R.K. Nandy, S.K. Bhattacharya, M.K. Bhattacharya, Jap. J. Infec. Diseas. 61, 128 (2008)
  • [9] W. Petri, Curr. Treat. Opt. Gastroenterol. 8, 13 (2005) http://dx.doi.org/10.1007/s11938-005-0047-3[Crossref]
  • [10] D.R. Guay, Drugs 68, 1169 (2008) http://dx.doi.org/10.2165/00003495-200868090-00002[Crossref]
  • [11] The United States Pharmacopeial Convention, The United States pharmacopeia, USP 31: the national formulary, NF 26 (The Convention, Rockville, MD, 2007)
  • [12] British Pharmacopoeia Commission. British Pharmacopoeia 2008. The Stationery Office, London, 2007)
  • [13] M.I. Walash, A.M. Elbrashy, M.A. Sultan, Anal. Lett. 26, 499 (1993) http://dx.doi.org/10.1080/00032719308016814[Crossref]
  • [14] E. Hammam, J. Pharm. Biom. Anal. 30, 651 (2002) http://dx.doi.org/10.1016/S0731-7085(02)00344-8[Crossref]
  • [15] N.M. Tendolkar, B.S. Desai, J.S. Gaudh, V.M. Shinde, Anal. Lett. 28, 1641 (1995) http://dx.doi.org/10.1080/00032719508002771[Crossref]
  • [16] Y.K. Agrawal, D.R. Patel, Anal. Lett. 19, 1289 (1986) http://dx.doi.org/10.1080/00032718608066301[Crossref]
  • [17] C. Bock, P. Gowik, C. Stachel, J. Chromatogr. B 856, 178 (2007) http://dx.doi.org/10.1016/j.jchromb.2007.05.044[Crossref]
  • [18] E.E.O. Manso, Z.R. Negrin, N.R.C. Cancio, J.A.P. Donato, H.Z.S. Perez, T.E.G. Placeres, J.J.G. Feitót, PCT Int. Appl. WO 2007131458, 16 (2007)
  • [19] J. Heukelbach, S.F. Walton, H. Feldmeier, Curr. Infect. Dis. Rep. 7, 373 (2005) http://dx.doi.org/10.1007/s11908-005-0012-2[Crossref]
  • [20] J. Heukelbach, H. Feldmeier, Lancet 363, 889 (2004) http://dx.doi.org/10.1016/S0140-6736(04)15738-3[Crossref]
  • [21] M.A. Taylor, Vet. J. 161, 253, (2001) http://dx.doi.org/10.1053/tvjl.2000.0549[Crossref]
  • [22] E. Colebrook, R. Wall, Vet. Parasitol. 120, 251 (2004) http://dx.doi.org/10.1016/j.vetpar.2004.01.012[Crossref]
  • [23] P. Willadsen, Parasitology 133, S9 (2006) http://dx.doi.org/10.1017/S0031182006001788[Crossref]
  • [24] G.A. Shabir, J. Chromatogr. A 987, 57 (2003) http://dx.doi.org/10.1016/S0021-9673(02)01536-4[Crossref]
  • [25] G.A. Shabir, W.J. Lough, S.A. Arain, T.K. Bradshaw, J. Liq. Chromatogr. Relat. Technol. 30, 311 (2007) http://dx.doi.org/10.1080/10826070601084753[Crossref]
  • [26] M. Ribani, C.B.G. Bottoli, C.H. Collins, I.C.S.F. Jardim, L.F.C. Melo, Quím. Nova 27, 771 (2004) http://dx.doi.org/10.1590/S0100-40422004000500017[Crossref]
  • [27] N.M. Cassiano, J.C. Barreiro, L.R.R. Martins, R.V. Oliveira, Q.B. Cass, Quim. Nova 32, 1021 (2009) http://dx.doi.org/10.1590/S0100-40422009000400033[Crossref]
  • [28] The United States Pharmacopeia, Validation of Compendial Procedures, 30th edition (United States Pharmacopeial Convention, Rockville, MD, 2007) Chap. 1225, 680–683
  • [29] ICH Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1), 1 (2005)
  • [30] ICH Harmonization Tripartite Guideline: 1995, Proceedings of the International Conference on Harmonization - Q2A: Text on validation of Analytical Procedures, Geneva, Switzerland
  • [31] ICH Harmonization Tripartite Guideline: 1997, Proceedings of the International Conference on Harmonization - Q2B: Validation of Analytical Procedures: Methodology, Geneva, Switzerland
  • [32] 4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Annex 1: Residue on Ignition/Sulphated Ash General Chapter Analytical Procedures and/or Acceptance Criteria (APAC). FDA 2006
  • [33] Specifications: Test Procedures and Acceptance Criteria For New Veterinary Drug Substances And New Medicinal Products: Chemical Substances VICH GL39. FDA 2006
  • [34] J.C. Miller, J.N. Miller, Statistic for Analytical Chemistry, 2nd edition (Ellis Harwood, New York, 1992)
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11532-012-0194-z
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.